Long non-coding RNAs are involved in alternative splicing and promote cancer progression

Jiawei Ouyang, Yu Zhong, Yijie Zhang, Liting Yang, Pan Wu, Xiangchan Hou, Fang Xiong, Xiayu Li, Shanshan Zhang, Zhaojian Gong, Yi He, Yanyan Tang, Wenling Zhang, Bo Xiang, Ming Zhou, Jian Ma, Yong Li, Guiyuan Li, Zhaoyang Zeng, Can Guo and Wei Xiong

© The Author(s), under exclusive licence to Springer Nature Limited 2021

Alternative splicing (AS) is a key process in which precursor RNAs produce different mature RNAs, and the disorder of AS is a key factor in promoting cancer development. Compared with coding RNA, studies on the functions of long non-coding RNAs (lncRNAs) are far from enough. In fact, lncRNA is an important participant and regulator in the process of AS. On the one hand, lncRNAs regulate cancer progression as products of precursor messenger RNA (mRNA), but on the other hand, precursor lncRNA generates cancer-related abnormal splicing variants through AS. In addition, lncRNAs directly or indirectly regulate the AS events of downstream target genes, thus affecting the occurrence and development of cancer. Here, we reviewed how lncRNAs regulate AS and influence oncogenesis in different ways.

BACKGROUND

Alternative splicing (AS) refers to a process in which precursor RNAs (pre-RNAs) produce different splicing variants through different splicing patterns, mainly including exon skipping, intron inclusion, mutually exclusive exons and alternative 5′ and 3′ splice sites [1, 2]. However, more than 90% of human genes undergo AS [3], which is not only an important mechanism for regulating gene expression and generating proteome diversity, but is also a key factor leading to the large differences in the number of eukaryotic proteins. Specifically, different coding regions of a gene can be spliced in different ways, resulting in multiple transcription states of the gene, and the final protein product may have different or mutually antagonistic functional and structural characteristics. Differences in expression at the transcriptional and protein levels result in different phenotypes and changes in biological processes that may play important roles in development, differentiation and cause various diseases, including cancer [4, 5]. However, abnormal AS involved in the abnormal regulation of certain genes during tumorigenesis is far from sufficiently elucidated.

The main factor that causes the AS of pre-RNAs is the co-regulation of cis-elements and trans-acting factors; the cis-elements are exon splice enhancer, exon splice silencer, intron splice enhancer and intron splice silencer. Serine- and arginine-rich splicing factors (SR proteins) and heterogeneous nuclear ribonucleoproteins (hnRNPs) are two famous families of trans-acting factors [6, 7]. In addition, transcription, m6A modification and chromosome structure can affect AS [8, 9]. Thus, the occurrence of abnormal AS is also closely related to the mutation or disorder of these splicing-related elements, causing the occurrence of cancer. However, with further research on the function of non-coding RNAs, studies have found that non-coding RNAs have more unique and interesting functions in the process of AS [10], especially long non-coding RNAs (lncRNAs).

LncRNA is a type of RNA molecule with a transcript longer than 200 nucleotides. A unique function of lncRNAs is that they interact with various molecules and can form a variety of RNA–RNA, RNA–DNA, or RNA–protein complexes through specific RNA functional domains, leading to lncRNA functional diversity [11–14]. For this reason, lncRNAs, as important regulatory molecules, play a key biological function in the occurrence and development of cancer through different pathways [15–23]. Previous studies have shown that lncRNAs can be used as products of AS to play a biological function in promoting or suppressing cancer. Furthermore, lncRNAs may also participate in the abnormal AS process of certain cancer-related genes through the regulation of precursor messenger RNA (pre-mRNA), encoding small peptides and association with splicing factors and so on.

This review aimed to elucidate the role of lncRNAs involved in AS and their influence on tumorigenesis in order to identify new pathways for the study of cancer pathological mechanisms and clinical treatment.

A product of AS of pre-mRNA: lncRNA

RNA splicing depends on the mutual cooperation of U1, U2, U4, U5 and U6 small nuclear ribonucleoproteins, and the whole
process is completed by two transesterification reactions [2]. The selection of splice sites in pre-RNA induced by multiple splicing factors is the main reason for the occurrence of AS. However, the AS of human genes is common and extensive, and the birth of lncRNA is also inseparable from such a process. It may be generated as a splicing product, especially in the process of tumour development, where the abnormally expressed lncRNA directly affects its downstream pathways and plays a specific biological function [24–28].

Previous studies have shown that IncRNA-PNUTS splicing isoforms are involved in epithelial-to-mesenchymal transition (EMT)-related tumour progression. Moreover, the splicing inhibitor hnRNPE1 can bind to the PNUTS pre-mRNA exon 12 splicing site to regulate the AS of PNUTS. When hnRNPE1 binds to this site, PNUTS pre-mRNA undergoes normal splicing to produce PNUTS mRNA, whereas, when hnRNPE1 dissociates from this site, PNUTS pre-mRNA produces the non-coding isoform IncRNA-PNUTS. Functionally, IncRNA-PNUTS can act as a sponge to compete for miR-205 to upregulate ZEB1, thereby inhibiting the expression of the epithelial marker E-cadherin and inducing EMT to promote tumorigenesis [29] (Fig. 1a).

**Fig. 1 A product of AS of pre-mRNA: lncRNA.** a Splicing factor hnRNPE1 promotes proximal 5′ splice-site selection in exon 12, thus inducing the production of PNUTS mRNA. The absence of hnRNPE1 facilitates the generation of the lncRNA-PNUTS isoform, which promotes tumour development by competitively binding with miR-205 to upregulate ZEB1. b IFNγ promotes the generation of the PD-L1-Inc isoform and PD-L1-Imm activates the transcriptional activity of c-myc through the formation of a heterodimer with Max to promote the development of tumours. c In oral squamous cell carcinoma, exon 2 and 3 skipping of ORAOV1 pre-mRNA leads to the formation of the IncRNA ORAOV1-B isoform, which activates the TNF-κB/TNFα loop pathway by binding with HSP90.

**AS of pre-lncRNA produces generate different lncRNAs**

LncRNA genes can also undergo AS and generate different lncRNA isoforms [32, 33]. However, the potential biological functions of most lncRNA isoforms have not been discovered, and more studies tend to focus on the variants with relatively high expression abundance. In fact, the functional mechanisms of lncRNA isoforms may be quite different [34]. It is proposed that splicing events at the lncRNA-associated enhancer RNA producing centre sites are associated with enhancer activity [35], but the findings of studies of the AS process of lncRNAs remain vague. MBNL3, a skeleton splicing factor, promotes tumorigenesis and indicates a poor prognosis for patients with hepatocellular carcinoma; it induces IncRNA-PXN-AS1 exon 4 inclusion by binding to IncRNA-PXN-AS1 intron 4 to promote liver cancer.
The transcript of lncRNA-PXN-AS1 lacking exon 4 can bind to the coding sequence of PXN mRNA and lead to the dissociation of translation elongation factors from PXN mRNA, thereby inhibiting the translation of PXN mRNA and inhibiting liver cancer. In addition, the transcript containing exon 4 preferentially binds to the 3′-untranslated regions (UTR) of PXN mRNA and protects the PXN mRNA from degradation induced by the microRNA-24–AGO2 complex, thereby increasing PXN expression and promoting liver cancer [36] (Fig. 2a).

LncRNA PVT1 combines with miR-200S to upregulate the expression of ZEB1, ZEB2 and BMI1 and promotes tumour growth in clear-cell renal cell carcinoma (ccRCC). Interestingly, PVT1 lacking exon 4 (PVT1ΔE4) is a new splice isoform that has a high expression level in ccRCC. Splicing factor SRSF1 promoted the skipping of exon 4 of PVT1 and induced the expression of splicing variant PVT1ΔE4. It can also competitively bind with miR-200s to regulate the expression of ZEB1, ZEB2 and BMI1 as full-length transcripts, and the specific mechanism needs to be further studied [37] (Fig. 2b). In summary, these studies suggest that studying the differences in AS isoforms of lncRNAs is helpful to further understand the biological function of lncRNAs in the process of cancer development.

**LncRNAs directly participate in the regulation of AS**

LncRNAs can be directly involved in the AS of target genes by means of their ability to form RNA–DNA duplexes [38] or RNA–RNA duplexes [39]. It is noteworthy that many of the lncRNAs that rely on complementary sequences to regulate AS are natural antisense transcripts.

**LncRNAs regulate AS by establishing a splicing-specific chromatin tag.** Whole-genome sequencing data revealed different chromatin landscapes on exon and intron sequences, confirming the role of chromatin as a splicing regulator. It has a unique splicing pattern by affecting the elongation of Pol II and specifically recruiting RNA-binding proteins that interact with chromatin-binding proteins [40]. The key issue in the regulation of chromatin-mediated splicing is the establishment and maintenance of regulatory chromatin domains. As partners of the chromatin modification complex and chromatin remodelling factor, lncRNAs play an important role in regulating the chromatin structure in tumours [41], which is highly likely to be a means for lncRNAs to regulate AS in tumours. However, the relationship between lncRNA and chromatin-mediated AS remains unclear.

A previous study revealed that an evolutionarily conserved nuclear antisense lncRNA-asFGFR2 generated from the human FGFR2 locus promotes FGFR2-specific AS. asFGFR2 recruits the EZH2 and SUZ12 of polycomb repressive complex 2 and histone demethylase KDM2a to the FGFR2 locus, forming a splicing-specific chromatin tag to generate a chromatin environment; it blocks the binding of the chromatin adaptor complex MRG15-PTB to exon IIIb and eventually induces the inclusion of FGFR2 exon IIIb. It has been proposed that asFGFR2 is directly involved in AS by recruiting chromatin modifiers to the site through sequence complementarity and the formation of RNA–DNA duplexes.
double strands with the parent DNA [42]. The FGFR2 IIIb isoform plays an antitumor role in hepatocellular carcinoma, which provides a new approach for the study and treatment of this highly aggressive tumor [43] (Fig. 3a).

LncRNAs interact with target pre-mRNAs to regulate AS. The formation of RNA–RNA duplexes is a major function of LncRNAs, which is also performed by LncRNAs in AS. Interestingly, many antisense LncRNAs will form duplexes with their sense pre-mRNA and participate in AS.

One of the first discovered pre-mRNA directly regulated by its antisense LncRNA for AS is ZEB2. ZEB2 pre-mRNA has a long 5'-UTR, and effective translation requires retention of the 5'-UTR containing the intron of the internal ribosome entry site (IRES) in the intron and promote the protein expression of ZEB2. Fas antisense transcription Saf binds to exon 6 of Fas pre-mRNA and recruits splicing factor SPF45 to facilitate the skipping of exon 6 and promote the generation of the sFas isoform, thereby inhibiting cell apoptosis and leading to tumor growth.

**Fig. 3** LncRNAs directly participate in the regulation of AS. a asFGFR2 recruits the EZH2 and SUZ12 of polycomb repressive complex 2 to its parent sites, triggering the recruitment of H3K36 demethylase enzyme KDM2a, thereby establishing a splicing chromatin tag that blocks the binding of chromatin adaptor complex MRG15-PTB to exon IIIb. This promotes the production of FGFR2 mRNA containing IIIb. b Snail1 promotes the formation of the RNA–RNA duplexes in introns of the 5'-UTR of parent RNA and prevents the removal of this intron during splicing. Then, the ribosome can be induced to recognize the internal ribosome entry site (IRES) in the intron and promote the protein expression of ZEB2. c Fas antisense transcription Saf binds to exon 6 of Fas pre-mRNA and recruits splicing factor SPF45 to facilitate the skipping of exon 6 and promote the generation of the sFas isoform, thereby inhibiting cell apoptosis and leading to tumor growth.
LncRNAs are indirectly involved in the regulation of AS. a PKM pre-mRNA can produce both PKM1 and PKM2 isoforms. HOXB-AS3 encodes a small peptide that competitively binds to the splicing factor hnRNPA1, thereby promoting the formation of PKM1 and ultimately inhibiting tumour growth.

b Sp4 pre-mRNA can produce both long variants (Sp4-L) and short variants (Sp4-S) by AS. By interacting with SRSF3, the small peptide encoded by LOC90024 promotes the inclusion of exon 3 of Sp4 pre-mRNA and the generation of Sp4-L, which is conducive to tumour development.

c TPM1-AS prevents the splicing effect of RBM4 on TPM1 by binding with the splicing factor RBM4, induces the generation of the TPM1 V1/V3/V4/V5 variant and inhibits the occurrence and development of tumour cells.

d Mcl-1 pre-mRNA generates Mcl-1S (pro-apoptotic) and Mcl-1L (anti-apoptotic) by AS. The interaction between DGCR5 and SRSF1 promotes the retention of exon 2 and the generation of Mcl-1L.

e MALAT1 hijacks SFPQ in the SFPQ/PTBP2 splicing factor complex, thereby causing the release of PTBP2 to promote tumour growth. Meanwhile, MALAT1 can control the transport and distribution of SR family proteins at transcription sites and among nuclear spots by affecting the phosphorylation of SR family proteins. MALAT1 forms a splicing complex with ID4, mut-P53 and SRSF1 to promote the distal 5’ splice-site selection of exon 8, promoting the generation of angiogenic isoform VEGFA_{xxx} (the subscript \( \times \times \times \) indicates the number of amino acids in different isoforms).
expression of ZEB2-anti, which combines with the ZEB2 5′-UTR intron to cover the splice donor that regulates the intron, inhibiting splicing and inducing translation to promote the occurrence of EMT [44] (Fig. 3b).

A major apoptosis pathway is triggered by the Fas receptor-Fas ligand (FasL) interaction. A lncRNA located in the nucleus, Fas antisense or Saf, interacts with the Fas pre-mRNA and splicing factor 45 to promote the cleavage of exon 6 [45]. The product is soluble Fas that can protect cells from Fas-FasL-induced apoptosis by binding to FasL (Fig. 3c).

In addition, BC200 has a carcinogenic effect in breast cancer. A study has found that BC200 contains a 17-nucleotide sequence complementary to Bcl-x pre-mRNA, which can promote its binding to Bcl-x pre-mRNA and the recruitment of the splicing factor hnrNPA2/B1. The hnrNPA2/B1 interferes with the binding of Bcl-x pre-mRNA and Bcl-x promotion factor Sam68, resulting in the blockade of Bcl-x expression, thereby promoting tumour occurrence [46]. Therefore, lncRNAs can interact with pre-mRNA and directly participate in the regulation of AS in cancers.

**LncRNAs are indirectly involved in the regulation of AS**

LncRNAs regulate AS through the encoded peptide. Although lncRNAs belong to a class of RNA molecules that have no or weak coding ability, with the development of bioinformatics and high-volume measurement, small open-reading frames in lncRNAs have been gradually discovered, which can play a biological function by encoding small peptides. Many studies have shown that small peptides encoded by lncRNAs also play an important role in the development of cancer [47–51].

A previous study identified a small peptide encoded by the lncRNA HOXB-AS3, which was named 53-amino acid (aa) peptide, and showed that patients with colon cancer (CRC) with low levels of 53-aa peptide have a poor prognosis. The 53-aa peptide competitively binds to the arginine residue in the RGG motif of the splicing factor hnrNPA1 and blocks the binding of hnrNPA1 to the PKM pre-mRNA, thereby inhibiting the cleavage of PKM exon 9, resulting in the reduced synthesis of PKM2, an isoenzyme of glycolytic pyruvate kinase, thereby inhibiting the reprogramming of glucose metabolism and ultimately inhibiting the growth of CRC [52] (Fig. 4a).

In addition, lncRNA LOC90024-encoded small peptide SRSF can bind splicing factor SRSF3 to induce the inclusion of transcription factor Sp4 exon 3, promote the generation of Sp4-L while inhibiting Sp4-S and promote tumorigenesis of CRC [53] (Fig. 4b).

LncRNAs regulate AS by interacting with splicing factors. Splicing factors play a central role in the regulation of AS by interacting with the sequence elements of pre-RNA, while lncRNAs often play the role of cooperating with or hijacking splicing factors to regulate AS.

A study found TPM1-AS, an uncharacterised lncRNA, which was reverse transcribed from the second intron of TPM1. TPM1-AS is located at the nucleus and interacts with the splicing factor RBM4 in human oesophageal cancer cells. The interaction between TPM1-AS and RBM4 hinders the binding of RBM4 to TPM1 pre-mRNA and inhibits the inclusion of endogenous exon 2a of TPM1, resulting in the specific downregulation of TPM1 variants V2 and V7 in human oesophageal cancer cells, and producing the TPM1 pre-mRNA variant V1, V3, V4 and V5, thereby inhibiting the migration and mitosis of human oesophageal cancer cells [54] (Fig. 4c).

In addition, lncRNA DGCR5 expression is upregulated in oesophageal squamous cell carcinoma (ESCC) and is associated with a poor prognosis. Researches have shown that DGCR5 interacts with SRSF1 and regulates the AS event of Mcl-1, which is conducive to the generation of the anti-apoptotic isoform Mcl-1L, thus promoting tumorigenesis [55] (Fig. 4d).

LncRNA MALAT1, as one of the classical lncRNAs associated with tumours, is highly expressed in many cancer types. Studies have shown that MALAT1 located in nuclear speckles can interact with a series of SR proteins such as SRSF1, SRSF2, SRSF3 and SRSF5 to varying degrees, and affect the transport and distribution of SR protein at transcription sites and between nuclear speckles by regulating the ratio of phosphorylation/dephosphorylation of SR proteins to regulate the AS events of pre-mRNAs [56]. Previous studies have shown that MALAT1 can up-regulate SRSF1-mediated series of cancer-promoting splicing events [57]. Another study showed that mutant p53 and ID4 proteins can form complexes with MALAT1 and SRSF1, regulate the AS of VEGFA pre-mRNA, inhibit the synthesis of the anti-angiogenic VEGFA isoform and promote angiogenic formation [58]. Not only does MALAT1 cooperate with the splicing factor but it also hijacks SFQ from the splicing factor complex SFQ/PTBP2 [59] (Fig. 4e).

Another study has shown that lncRNA uc002yug.2 is generally overexpressed in ESCC. LncRNA uc002yug.2 promotes the binding of SRSF1, MBNL1 and other splicing factors to the RUNX1 pre-mRNA, thereby upregulating the expression of RUNX1a and downregulating the expression of RUNX1 to reduce the expression level of the gene CEBPa and promote cell proliferation and tumorigenesis [60]. Meanwhile, in colorectal cancer, LINCO1133 can interact with SRSF6 to inhibit the occurrence of EMT. Whether this lncRNA acts as a repressor of SRSF6 and, thus, affects the AS process of SRSF6-mediated EMT-related molecules remains to be studied [61]. In addition, lnc01232 interacts with the splicing factor hnrNPA2/B1 and stabilises hnrNPA2/B1 by inhibiting hnrNPA2/B1 ubiquitination and degradation to promote the expression of its splicing target A-Raf full-length, thereby promoting pancreatic cancer [62]. These studies have revealed a new mechanism in which lncRNA regulates the splicing of target genes by interacting with splicing factors, thereby exerting a biological function of promoting or suppressing cancer.

**Bioinformatics tools for predicting lncRNAs and AS**

Only a few studies have confirmed the close relationship between lncRNAs and AS. It is necessary to predict the AS events mediated by lncRNAs and the abundance of each transcript through bioinformatics methods. Most of the algorithms are based on the application of RNA-seq (RNA-seq) data sources and mathematical models, which will allow a more systematic and comprehensive understanding of the AS events of lncRNAs or the potential sequence functions, regulatory factors and biomarkers [66]. Meanwhile, in recent years, the RNA-seq data of liver cancer tissues and normal liver tissues from TCGA and GTEX-RNA were used to identify non-coding genes and AS isoforms with different expressions, and the physical interaction information network between lncRNAs and target genes was integrated through data mining. Finally, the RWMG model algorithm was used to analyse and predict the lncRNAs related to AS. This is the first time that a large-scale complex network has been integrated to predict the lncRNAs that regulate AS events in cancers, which is of great significance for discovering potential tumour markers [67].

**PERSPECTIVE**

As the most critical switch in RNA processing, AS strictly controls the physiological order at the transcriptome level and micro-regulates all aspects of biological effects in cells. Abnormal changes in AS make genes produce splicing isoforms after transcription and encode abnormal proteins. Splicing isoforms are related to cancer-related cell migration, cell growth regulation, hormone responsiveness, cell death and changes in gene...
| LncRNA name         | Classification of AS | Tumour types                                      | Mechanism of AS                      | Function                                                                 | Reference |
|---------------------|----------------------|--------------------------------------------------|--------------------------------------|--------------------------------------------------------------------------|-----------|
| PNUTS               | An AS product of pre-mRNA, the product of this lncRNA promotes the formation of PUNTS pre-mRNA | Lung cancer, breast cancer, prostate cancer, colorectal adenocarcinoma | Competitively binds with miR-205 to upregulate ZEB1 to promote tumorigenesis | Lung adenocarcinoma, breast cancer, prostate cancer, colorectal adenocarcinoma |
| PD-L1-Inc           | An AS product of pre-mRNA | Lung cancer                                        | Competitively binds with miR-205 to upregulate ZEB1 to promote tumorigenesis | Lung cancer |
| ORAOV1-B            | An AS product of pre-mRNA | Lung cancer, breast cancer, colorectal adenocarcinoma | Combines Hsp90 activation of TNF-κB/TNFα loop and predominantly promotes HIF1α | Ovarian squamous cell carcinoma, acute myeloid leukemia |
| PNX-AS1-S           | An AS product of pre-lncRNA | Lung cancer, breast cancer, colorectal adenocarcinoma | Inhibits the translation of PNX, thus promoting tumorigenesis | Colorectal cancer, lung cancer, acute myeloid leukemia |
| PVT1ΔE4             | An AS product of pre-lncRNA | Clear-cell renal cell carcinoma                    | Competitively binds with miR-200s to regulate the expression of ZEB1, ZEB2 and BMI1 to promote tumorigenesis | Clear-cell renal cell carcinoma, breast cancer |
| CRNDE-g             | An AS product of pre-lncRNA | Colorectal cancer, glioma, acute myeloid leukaemia | Directly interacts with miR-181a-5p to inhibit the degradation of Bcl-2 mRNA, thereby inhibiting cell apoptosis | Colorectal cancer, glioma, acute myeloid leukaemia |
| LHFPL3-AS1-long     | An AS product of pre-lncRNA | Melanoma                                           | Directly interacts with miR-181a-5p to inhibit the degradation of Bcl-2 mRNA, thereby inhibiting cell apoptosis | Melanoma |
| SOX2OT V4/V7        | An AS product of pre-lncRNA | Non-small cell lung tumour, breast cancer          | Binds to ZEB2 pre-mRNA to inhibit intron splicing at the 5′-UTR to induce ZEB2 translation | Non-small cell lung tumour, breast cancer |
| asFGFR2             | Establishing a splice-specific chromatin tag that damages the chromatin adaptor complex MRG15-PTB binding to the gene, and induces the inclusion of FGFR2 exon IIIb | Hepatocellular carcinoma, glioblastoma, non-small cell lung cancer, breast cancer | Promotes the generation of the antitumor FGFR2 IIIb isoform by regulating AS | Hepatocellular carcinoma, glioblastoma, non-small cell lung cancer, breast cancer |
| ZEB2-anti           | Binding to the target pre-mRNA | Breast cancer                                       | Binds to ZEB2 pre-mRNA to inhibit intron splicing at the 5′-UTR to induce ZEB2 translation | Breast cancer |
| UXT-AS1             | Binding to the target pre-mRNA | Colon cancer                                        | Binds to ZEB2 pre-mRNA to inhibit intron splicing at the 5′-UTR to induce ZEB2 translation | Colon cancer |
| Sf                  | Binding to the target pre-mRNA | Erythroleukaemia, cervical carcinoma                | Binds to ZEB2 pre-mRNA to inhibit intron splicing at the 5′-UTR to induce ZEB2 translation | Erythroleukaemia, cervical carcinoma |
| BC200               | Binding to the target pre-mRNA | Breast cancer                                       | Binds to ZEB2 pre-mRNA to inhibit intron splicing at the 5′-UTR to induce ZEB2 translation | Breast cancer |
| Ai-lncRNA EGOT      | Binding to the target pre-mRNA | Lung adenocarcinoma, breast cancer                 | Binds to ZEB2 pre-mRNA to inhibit intron splicing at the 5′-UTR to induce ZEB2 translation | Lung adenocarcinoma, breast cancer |
| PLANER              | Cooperates with hnRNPA1 to regulate an alternative 5′′ splice site within intron 45 of NCO2 pre-mRNA | | Cooperates with hnRNPA1 to regulate an alternative 5′′ splice site within intron 45 of NCO2 pre-mRNA | Cooperates with hnRNPA1 to regulate an alternative 5′′ splice site within intron 45 of NCO2 pre-mRNA |
| LncRNA name       | Classification of AS                                      | Mechanism of AS                                                                 | Function                                                                 | Tumour types                  | Reference |
|-------------------|----------------------------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------|-------------------------------|-----------|
| HOXB-AS3          | Encoding small peptides and mediating alternative splicing | The encoding peptide hijacks the splicing factor hnRNPA1 to induce exon 9 to include PKM pre-mRNA and promote PKM1 formation | Promotes the generation of the PKM1 isoform through AS and regulates the metabolic reprogramming of tumour cells | Colon cancer                 | [52]     |
| LOC90024          | Encoding small peptides and mediating alternative splicing | The small peptide SRSP binds to the splicing factor SRSF3 to induce the exon 3 skipping of Sp4 and promote the formation of the Sp4-L isoform | Promotes tumorigenesis and progression by inducing the formation of the Sp4-L isoform through AS | Colorectal cancer             | [53]     |
| LincRNA-uc002yug.2| Interacting with splicing factors                         | Cooperates with SRSF1 and MBNL1 to regulate the AS of RUNX1 pre-mRNA and promote the generation of RUNX1a | Induces the generation of the RUNX1a isoform by AS and leads to the decrease of CEBPα expression, which promotes tumorigenesis | Oesophageal squamous cell carcinoma | [60]     |
| SNHG6             | Interacting with splicing factors                         | SNHG6 can target PKM mRNA and induce hnRNPA1-specific splicing of PKM pre-mRNA | Leads to metabolic reprogramming of tumour cells by regulating AS         | Colorectal cancer             | [92]     |
| TPM1-AS           | Interacting with splicing factors                         | Hijacks RBM4 to prevent its binding to TPM1 pre-mRNA and inhibits exon 2A inclusion, inducing downregulation of the expression of V2 and V7 variants | Inhibits migration and mitotic formation of human oesophageal cancer cells by regulating the AS of TPM1 pre-mRNA | Oesophageal cancer             | [54]     |
| Linc01232         | Interacting with splicing factors                         | Participates in the AS of A-Raf by stabilising HNRNPA2B1 and promoting the generation of the A-RAF-FL isoform | The Linc01232/hnRNPA2B1/A-Raf /MAPK axis promotes tumorigenesis           | Pancreatic cancer             | [62]     |
| DGCR5             | Interacting with splicing factors                         | Cooperates with SRSF1 to regulate the AS of Md-1 pre-mRNA and the inclusion of exon 2 to induce the production of Md-1-L | Induces tumorigenesis by regulating AS to promote the generation of anti-apoptotic Md-1-L | Squamous cell carcinoma of the oesophagus | [55]     |
| CRNDE             | Interacting with splicing factors                         | Promotes the generation of the PICALML isoform by stabilising SRSF6 involved in the alternative splicing of PICALM pre-mRNA and the inclusion of exon 14 | Regulates the AS of PICALM pre-mRNA and is involved in autophagy-induced drug resistance in tumour cells | Gastric cancer                | [93]     |
| LUCAT1            | Interacting with splicing factors                         | Cooperates with PTBP1 to regulate AS of APP, CD44, CLSTN1, MBNL1 and ZNF207 | Regulates the AS of a series of genes related to DNA damage and induces drug resistance of tumour cells | Colorectal cancer             | [80]     |
| PCGEM1            | Interacting with splicing factors                         | Interacts with splicing factors hnRNPA1 and U2AF65 to regulate the AS of androgen receptor (AR) pre-mRNA and the expression of AR3 variants | Regulates the expression of AR3 by interacting with splicing factors       | Prostate cancer               | [94]     |
| PNCTR             | Interacting with splicing factors                         | Hijacks PTBP1 to regulate the AS of CHEK pre-mRNA and the inclusion of exon 8, thereby promoting the generation of the CHEK-L isoform and the development of tumours | Promotes the expression of CHEK-L through the AS mechanism and induces tumorigenesis | Cervical cancer               | [95]     |
| LINC01348         | Interacting with splicing factors                         | LINC01348 complex with splicing factor 3B subunit 3 (SF3B3) acts as a modulator of EZH2 pre-mRNA and promotes the skipping of exon 14 of target gene EZH2 pre-mRNA | LINC01348/SF3B3/EZH2/JNK/c-Jun/Snail signalling pathways inhibit tumorigenesis | Hepatocellular carcinoma      | [83]     |
expression in chemotherapy responses and become tumour biomarkers and molecular targets [68, 69]. There is evidence that splicing mutations affecting oncogenes, tumour suppressor genes and other cancer-related genes occur during the initiation and development of cancer and there is a causal link. However, the mechanism leading to abnormal splicing during tumorigenesis remains unclear. Various studies have shown that genetic and somatic mutations in cis-acting elements, as well as variations in the composition, concentration, location and activity of trans-regulators affect the recognition and function of splice sites and promote the development of cancers [5, 70, 71].

LncRNAs account for a considerable proportion of the human transcriptome. Due to the long length and poorly conserved characteristics of IncRNAs, their structure and function are much more complex than that of coding genes, but their main function is to regulate gene expression [15]. Recent studies have shown that IncRNA plays an important role in normal life activities and the development of diseases. In various human cancers, many IncRNAs are involved in transcriptional activation regulation, epigenetic regulation and signal transduction to affect the proliferation, apoptosis, invasion and metastasis, DNA damage repair, metabolism and drug resistance of cancer cells [72–79].

However, in the past decade, studies on the mechanism of lncRNAs participating in the process of AS have gradually attracted attention. Similarly, lncRNAs, as splicing regulators, affect these characteristics of malignant tumour cells. For example, hypoxia-induced lncRNA LUCAT1 can cause chemotherapy resistance in colorectal cancer. These chemotherapy drugs are all DNA damage inducers, while lncRNA LUCAT1 causes AS of a series of DNA damage-related genes by binding splicing factor PTBP1 [80]. In addition, Ai-lncRNA EGOT can recruit hnRNPH1 to enhance the AS of pre-ITPR1 and form pre-ITPR1/EGOT double-stranded RNA to upregulate the expression of ITPR1, leading to the sensitivity of breast cancer cells to paclitaxel toxicity [81]. These findings suggest that it is very important to understand the mechanism of IncRNA-associated AS to solve the problem of drug resistance. Meanwhile, the AS events in the metabolic pathway regulated by IncRNAs are worthy of our attention. A study has found that IncRNA CCAT2 is involved in the AS process of glutaminase. Interestingly, CCAT2 is a lncRNA containing the single-nucleotide polymorphism (SNP) rs6983267. It reported that the allele of this SNP locus leads to different incidences of colorectal cancer. The authors found that different alleles of CCAT2 have different affinities for the subunit cleavage factor I25 (CFIm25) and CFIm68 of CFIm, so that changes in the interaction between CCAT2, CFIm and glutaminase pre-mRNA result in different splicing results [82]. This ultimately leads to the metabolic reprogramming of tumour cells. Of course, IncRNAs are not only supporters of cancer-promoting splicing isoforms. LINC01348 interacts with splicing factor SF3B3 to promote the skipping of exon 14 of EZH2 pre-mRNA. Eventually, the LINC01348/SF3B3/EZH2/JNK/c-Jun/Snail pathway inhibits hepatocellular carcinoma progression [83]. LINC01133 has also been reported to interact with SRSF6 to inhibit EMT and metastasis in colorectal cells [61]. These studies suggest that IncRNA is extensively involved in the regulation of AS events in the tumorigenesis mechanism. In addition to cancer, IncRNAs also influence AS events in other diseases. The IncRNA GOMAFU can change the AS events of schizophrenia-related genes DISC1 and ERBB4, and GOMAFU can interact with splicing factors QKI and SRSF1, which may be the mechanism of GOMAFU participating in the AS process [84]. The IncRNA Ctcfos is an important regulator of PRDM16, a key Brite fat-forming factor, which can regulate the splicing variant’s abundance of PRDM16, and then microregulate its function to regulate the production of Brite fat, which has research value in the treatment of obesity diseases and related comorbidities [85]. Therefore, the mechanism of IncRNA-associated AS in other diseases is worth in-depth study.
Understanding the potential relationship between lncRNAs and AS may improve our understanding of cancer mechanisms. Because of its selective anti-proliferative effect on cancer cells, the cold atmospheric plasma (CAP) is considered a potential alternative or complementary tool for cancer treatment and has been widely used in medicine in recent years. At present, studies have shown that CAP can kill a variety of tumours, but its tumour suppressor mechanism remains unclear. Studies have reported that CAP treatment of breast cancer cell line MCF-7 with different treatment conditions (600 s, 10 × 30 s) induces the opposite expression of ZNRD1 and its antisense lncRNA ZNRD1-AS1. When the CAP treatment condition is 600 s, the expression of ZNRD1 in MCF-7 cells is downregulated, while the expression of ZNRD1-AS1 is upregulated. This study has not yet discovered the specific mechanism of action between ZNRD1 and ZNRD1-AS1. However, the base complementary pairing of antisense lncRNA and sense mRNA is closely related to the AS mechanism, which is also likely to be one of the means to help formulate CAP treatment plans.

In general, the “butterfly effect mechanism” of lncRNA microregulates the expression of splicing isoforms of genes and then changes their functional effects in the mechanism pathway, which is of great research significance and provides new ideas and strategies for cancer research and clinical treatment. However, the involvement of lncRNAs in AS to regulate tumorigenesis is a relatively new research field. Few studies have investigated AS-related IncRNAs, and there is a need to develop effective systems biology approaches to develop a cancer-related IncRNA and AS events comprehensive network diagram to predict more relevant splicing isoforms of IncRNAs and discover new AS mechanisms to identify more potential biomarkers. In addition, one of the major challenges in current research is the lack of experimental animal models related to splicing isoforms, which is indispensable for linking basic research with clinical practice. Another challenge is the development of effective targeted drugs that target small molecules that regulate key cancer-related AS events, such as IncRNAs, and the development of splicing drugs will be a significant step towards personalised therapy in the future.

CONCLUSION

In this review, we discussed the mechanism of how lncRNAs participate in the regulation of AS in different ways and how they are involved in the regulation of certain tumorigenesis processes (Table 1). Specifically, lncRNAs can either become a cancer-associated splicing isoform or regulate the generation of cancer splicing variants of target genes. This may help us to further understand the molecular mechanism of cancer occurrence and development and find a new therapeutic method for cancer treatment.

DATA AVAILABILITY

Not applicable.

REFERENCES

1. Liu S, Cheng C. Alternative RNA splicing and cancer. Wiley Interdiscip Rev RNA. 2013;4:547–66.
2. Bonnell SC, López-Oreja I, Valcárcel J. Roles and mechanisms of alternative splicing in cancer—implications for care. Nat Rev Clin Oncol. 2020;17:457–74.
3. Wang ET, Sandberg R, Luo S, Kreshuk I, Zhang L, Mayr C, et al. Alternative isoform regulation in human tissue transcriptomes. Nature 2008;456:470–6.
4. Hu X, Harvey SE, Zheng R, Lyu J, Grzeskowiak CL, Powell E, et al. The RNA-binding protein AKAP8 suppresses tumor metastasis by antagonizing EMT-associated alternative splicing. Nat Commun. 2020;11:486.
5. Alsaafari S, Hovy A, Battistella A, Popova T, Wassif M, Henry E, et al. Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage. Nat Commun. 2016;7:10615.
6. Jeong S. SR proteins: binders, regulators, and connectors of RNA. Mol Cells. 2017;40:1–9.
7. Kędzierska H, Piekielko-Witkowska A. Splicing factors of SR and hnRNP families as regulators of apoptosis in cancer. Cancer Lett. 2017;396:53–65.
8. Zhu LY, Zhu YR, Dai DJ, Wang X, Jin HC. Epigenetic regulation of alternative splicing. Am J Cancer Res. 2018;8:2346–58.
9. Tan F, Zhao M, Xiong F, Wang Y, Zhang S, Gong Z, et al. N6-methyladenosine-dependent signalling in cancer progression and insights into cancer therapies. J Exp Clin Cancer Res. 2021;40:146.
10. Liu Y, Liu X, Lin C, Jia X, Zou H, Song J, et al. Noncoding RNAs regulate alternative splicing. J Exp Clin Cancer Res. 2021;40:11.
11. Fan C, Tang Y, Wang J, Xiong F, Guo C, Wang Y, et al. Role of long non-coding RNAs in glucose metabolism in cancer. Mol Cancer. 2017;16:130.
12. Tang Y, He Y, Zhang P, Wang J, Fan C, Yang L, et al. LncRNAs regulate the cytokineskeleton and related Rho/ROCK signaling in cancer metastasis. Mol Cancer. 2018;17:77.
13. Wang W, Zhou R, Wu Y, Liu Y, Su W, Xiong W, et al. PVT1 promotes cancer progression via microRNAs. Front Oncol. 2019;9:609.
14. Wang D, Zeng Z, Zhang S, Xiong F, He B, Wu Y, et al. Epstein-Barr virus-encoded miR-BART6-3p inhibits cancer cell proliferation through the LOCCS53103-STMN1 axis. FASEB J. 2020;34:8012–27.
15. Choudhary R, Sedano MJ, Harrison AL, Subramani R, Lin KY, Ramos El, et al. Long noncoding RNAs in cancer: from discovery to therapeutic targets. Adv Clin Chem. 2020;59:105–47.
16. He Y, Jing Y, Wei F, Tang Y, Yang L, Luo J, et al. Long non-coding RNA PVT1 predicts poor prognosis and induces radioresistance by regulating DNA repair and cell apoptosis in nasopharyngeal carcinoma. Cell Death Dis. 2018;9:235.
17. Bo H, Fan L, Li J, Liu Z, Zhang S, Shi L, et al. High expression of IncRNA AFAF1-AS1 promotes the progression of colon cancer and predicts poor prognosis. J Cancer. 2019;10:4677–83.
18. Lia N, Yiong F, Yang L, Bo H, Gong Z, Wang Y, et al. Long noncoding RNA AFAF1-AS1 acts as a competing endogenous RNA of miR-432-5p to facilitate nasopharyngeal carcinoma metastasis through regulating the Rho/Rac pathway. J Exp Clin Cancer Res. 2018;37:253.
19. Wei F, Jing YZ, He Y, Tang Y, Yang LT, Wu YF, et al. Cloning and characterization of the putative AFAF1-AS1 promoter region. J Cancer. 2019;10:1145–53.
20. Bo H, Fan L, Gong Z, Liu Z, Shi L, Guo C, et al. Upregulation and hypomethylation of IncRNA AFAF1-AS1 predicts a poor prognosis and promotes the migration and invasion of cervical cancer. Oncol Rep. 2019;41:4231–9.
21. Fan C, Tang Y, Wang J, Wang Y, Xiong F, Zhang S, et al. Long non-coding RNA LOCA284454 promotes migration and invasion of nasopharyngeal carcinoma via modulating the Rho/Rac signaling pathway. Carcinogenesis 2019;40:380–91.
22. Tang T, Yang L, Cao Y, Wang M, Zhang S, Gong Z, et al. LncRNA AATBC regulates Pinin to promote metastasis in nasopharyngeal carcinoma. Mol Oncol. 2020;14:2221–70.
23. Jin K, Wang S, Zhang Y, Xia M, Mao Y, Li X, et al. Long non-coding RNA PVT1 interacts with MYC and downstream molecules to synergistically promote tumorigenesis. Cell Mol Life Sci. 2019;76:4275–89.
24. Zhong Y, Yang L, Xiong F, He Y, Tang Y, Shi L, et al. Long non-coding RNA AFAF1-AS1 accelerates lung cancer cells migration and invasion by interacting with SNIP1 to upregulate c-Myc. Signal Transduct Target Ther. 2021;6:240.
25. Xiong F, Zhu K, Deng S, Huang H, Yang L, Gong Z, et al. AFAF1-AS1: a rising star among oncogenic long non-coding RNAs. Sci China Life Sci. 2021;64:1602–1611.
26. Wang M, Dai M, Wang D, Tang T, Xiong F, Xiong B, et al. The long noncoding RNA AATBC promotes breast cancer migration and invasion by interacting with YBX1 and activating the YAP1/ Hippo signaling pathway. Cancer Lett. 2022;512:60–72.
27. Zhu K, Gong Z, Li P, Jiang X, Zeng Z, Xiong W, et al. A review of lncRNA00673 as a novel IncRNA for tumor regulation. Int J Med Sci. 2021;18:398–405.
28. Deng X, Xiong W, Jiang X, Zhang S, Li Z, Zhou Y, et al. LncRNA LINC00472 regulates cell stiffness and inhibits the migration and invasion of lung adenocarcinoma by binding to YBX1. Cell Death Dis. 2020;11:945.
29. Grelet S, Link LA, Howley B, Obellianne C, Palamisyam V, Ganganarug VA, et al. A regulated PNUMs mRNA to IncRNA splice switch mediates EMT and tumour progression. Nat Cell Biol. 2017;19:1105–15.
30. Qu S, Jiao Z, Lu G, Yao B, Wang T, Rong W, et al. PD-L1 IncRNA splice isoform promotes lung adenocarcinoma progression via enhancing c-Myc activity. Genome Biol. 2021;22:104.
31. Luo X, Jiang Y, Chen F, Wei Z, Qiu Y, Xue H, et al. ORAI1-B promotes OSCC metastasis via the NF-kB-TNFα loop. J Dent Res. 2021;100:858–67.
32. Choudhari R, Yang B, Rotwein P, Gadad SS. Structure and expression of the long noncoding RNA gene MIR503 in humans and non-human primates. Mol Cell Endocrinol. 2020;510:110819.

British Journal of Cancer (2022) 126:1113 – 1124

J. Ouyang et al.
33. Iyer MK, Nkikafs YS, Malik R, Singhal U, Sahu A, Hosono Y, et al. The landscape of long noncoding RNAs in the human transcriptome. Nat Genet. 2015;47:199–208.
34. Sahebi R, Malakootian M, Balalae B, Shahyari A, Khoshnia M, Abbaszadegan MR, et al. Lnc-ROR and its spliced variants 2 and 4 are significantly up-regulated in esophageal squamous cell carcinoma. Iran J Basic Med Sci. 2016;19:1131–5.
35. Gil N, Ultsky I. Production of spliced long noncoding RNAs specifies regions with high potential for sequence enhancement. Cell Syst. 2017;5:537–47.
36. Yuan JH, Liu XN, Wang TT, Pan W, Tao QF, Zhou WP, et al. The MBNL3 splicing factor promotes hepatocellular carcinoma by increasing PXN expression through the alternative splicing of IncRNA-PXN-AS1. Nat Cell Biol. 2017;19:820–32.
37. Yang T, Zhou H, Liu P, Yan L, Yao W, Chen K, et al. IncRNA PVT1 and its splicing variant function as competing endogenous RNA to regulate clear cell renal cell carcinoma progression. Oncotarget. 2017;8:85353–67.
38. Koziol MJ, Rinn JL. RNA traffic control of chromatin complexes. Curr Opin Genet Dev. 2020;62:142–8.
39. Yang G, Lu X, Yuan L. LncRNA: a link between RNA and cancer. Biochim Biophys Acta. 2014;1839:1097–109.
40. Haque N, Oberdoerffer S. Chromatin and splicing. Methods Mol Biol. 2014;1126:97–113.
41. Han P, Chang CP. Long non-coding RNA and chromatin remodeling. RNA Biol. 2015;12:1094–8.
42. Gonzalez I, Munita R, Agirre E, Dittmer TA, Gyyling K, Misteli T, et al. A lncRNA regulates alternative splicing via establishment of a splicing-specific chromatin signature. Nat Struct Mol Biol. 2015;22:370–6.
43. Amann T, Bataille F, Sprusis T, Dittmer K, Wild P, Liedtke C, et al. Reduced expression of fibrillarin growth factor receptor zillib in hepatocellular carcinoma induces a more aggressive growth. Am J Pathol. 2010;176:1433–42.
44. Beltran M, Puig I, Peña C, Garcia JM, Alvarez AB, Peña R, et al. A natural antisense transcript regulates Zeb2/Sip1 gene expression during Snail1-induced epithelial-mesenchymal transition. Genes Dev. 2008;22:756–69.
45. Villamariz O, Chambers CB, Riberyd JM, Persons DA, Wilber A. Long noncoding RNA Saf and splicing factor 45 increase soluble Fas and resistance to apoptosis. Oncotarget. 2016;7:13810–26.
46. Singh R, Gupta SC, Peng WX, Zhou N, Pochampally R, At J, et al. A peptide encoded by the nuclear-retained long non-coding RNA LOC90024 promotes tumour growth and metastasis in colorectal cancer through binding to FPPQ and releasing oncogene PTBP2 from FPPQ/PTBP2 complex. Br J Cancer. 2014;111:736–48.
47. Cai T, Zhang Q, Wu B, Wang J, Li N, Zhang T, et al. LncRNA-encoded micro-ribonucleic acid regulates the alternative splicing of tropomyosin I through an interaction with RNA-binding motif protein 4. Int J Biochem Cell Biol. 2020;129:106231.
48. Wang Y, Wu S, Zhu X, Zhang L, Deng J, Li F, et al. Long non-coding RNA expression profiles and related regulatory networks in areca nut chewing-induced tongue squamous cell carcinoma. Oncol Lett. 2020;20:302.
49. Fan C, Wang J, Tang Y, Zhang S, Xiong F, Guo C, et al. Upregulation of long non-coding RNA LOCI8445 may serve as a novel diagnostic biomarker for head and neck cancers. BMC Cancer. 2020;20:917.
50. Wu Y, Wang D, Wei F, Xiong F, Zhang S, Gong Z, et al. EBV-miR-BART12 accelerates migration and invasion in EBV-associated cancer cells by targeting tubulin polymerization-promoting protein 1. FASEB J. 2020;34:16205–23.
51. Ge J, Wang J, Xiong F, Jiang X, Zhu K, Yu Y, et al. Epstein-Barr virus-encoded circular RNA circBART2.2 promotes immune escape of nasopharyngeal carcinoma by regulating PD-L1. Cancer Res. 2021;81:5074–5088.
52. Fan C, Zhang S, Gong Z, Li J, Tang R, Deng H, et al. Emerging role of metabolic reprogramming in tumor immune evasion and immunomodulation. Sci China Life Sci. 2021;64:534–47.
53. Wang D, Tang L, Wu Y, Fan C, Zhang S, Xiang B, et al. Abnormal X chromosome inactivation and tumor development. Cell Mol Life Sci. 2020;77:2949–58.
54. Fan CM, Wang JP, Tang YY, Zhao J, He SY, Xiong F, et al. circRNA-MAN1A2 could serve as a novel serum biomarker for malignant tumors. Cancer Sci. 2019;110:2180–8.
55. Tang L, Xiong W, Zhang L, Wang D, Wang Y, Yu Y, et al. circSETD3 regulates MAPRE1 through miR-515-5p and miR-1538 sponges to promote migration and invasion in nasopharyngeal carcinoma. Oncogene 2021;40:307–21.
56. Huan L, Guo T, Wu Y, Xu L, Huang S, Xu Y, et al. Hypoxia induced LUCAT1/PTBP1 axis modulates cancer cell viability and chemotherapy response. Mol Cancer. 2020;19:11.
57. Xu S, Wang P, Zhang J, Wu H, Sui S, Zhang J, et al. Ai-lncRNA EGOT enhancing autophagy sensitizes paclitaxel cytotoxicity via upregulation of ITPR1 expression by RNA-RNA and RNA-protein interactions in human cancer. Mol Cell. 2019;18:1889–90.
58. Redis RS, Vela LE, Lu W, Ferreira de Oliveira J, Ivan C, Rodriguez-Aguayo C, et al. Allele-specific reprogramming of long non-coding RNA CATAT. Mol Cell. 2016;61:520–34.
59. Lin YH, Wu MH, Liu YC, Lyu PC, Yeh CT, Lin KH. LINCOL3148 suppresses hepatocellular carcinoma metastasis through inhibition of SF3B3-mediated E2H2 pre-mRNA splicing. Oncogene. 2021;40:4675–85.
60. Barry G, Briggs JA, Vanichkina DP, Poth EM, Beveridge NJ, Ratnu VS, et al. The long non-coding RNA Gomafu is acutely regulated in response to neuronal
activation and involved in schizophrenia-associated alternative splicing. Mol Psychiatry. 2014;19:486–94.
85. Bast-Habersbrunner A, Kiefer C, Weber P, Fromme T, Schießl A, Schwalie PC, et al. LncRNA Ctcflos orchestrates transcription and alternative splicing in thermogenic adipogenesis. EMBO Rep. 2021;22:e51289.
86. Kim HW, Jeong D, Ham J, Kim H, Ji HW, Choi EH, et al. ZNRD1 and its antisense long noncoding RNA ZNRD1-AS1 are oppositely regulated by cold atmospheric plasma in breast cancer cells. Oxid Med Cell Longev. 2020;2020:9490567.
87. Ma X, Zhang W, Zhang R, Li J, Li S, Ma Y, et al. Overexpressed long noncoding RNA CRNDE with distinct alternatively spliced isoforms in multiple cancers. Front Med. 2019;13:330–43.
88. Zhang S, Wan H, Zhang X. LncRNA LHFPL3-AS1 contributes to tumorigenesis of melanoma stem cells via the miR-181a-5p/BCL2 pathway. Cell Death Dis. 2020;11:950.
89. Saghaeian Jazi M, Samei NM, Ghanei M, Shadmehr MB, Mowlu SJ. Over-expression of the non-coding SOX2OT variants 4 and 7 in lung tumors suggests an oncogenic role in lung cancer. Tumour Biol. 2016;37:10329–38.
90. Yin J, Luo W, Zeng X, Zeng L, Li Z, Deng X, et al. UXT-AS1-induced alternative splicing of UXT is associated with tumor progression in colorectal cancer. Am J Cancer Res. 2017;7:662–72.
91. Teng L, Feng YC, Guo ST, Wang PL, Qi TF, Yue YM, et al. The pan-cancer IncRNA PLANE regulates an alternative splicing program to promote cancer pathogenesis. Nat Commun. 2021;12:3734.
92. Lan Z, Yao X, Sun K, Li A, Liu S, Wang X. The interaction between lncRNA SNHG6 and hnRNP A1 contributes to the growth of colorectal cancer by enhancing aerobic glycolysis through the regulation of alternative splicing of PKM. Front Oncol. 2020;10:3363.
93. Zhang F, Wang H, Yu J, Yao X, Yang S, Li W, et al. LncRNA CRNDE attenuates chemoresistance in gastric cancer via SRSF6-regulated alternative splicing of PICALM. Mol Cancer. 2021;20:6.
94. Zhang Z, Zhou N, Huang J, Ho TT, Zhu Z, Qiu Z, et al. Regulation of androgen receptor splice variant AR3 by PCGEM1. Oncotarget. 2016;7:15481–91.
95. Yap K, Mukhtina S, Zhang G, Tan JSC, Ong HS, Makeyev EV. A short tandem repeat-enriched ma assembles a nuclear compartment to control alternative splicing and promote cell survival. Mol Cell. 2018;72:525–40. e13
96. Gordon MA, Babbs B, Cochran DR, Bitler BG, Richer JK. The long non-coding RNA MALAT1 promotes ovarian cancer progression by regulating RBFOX2-mediated alternative splicing. Mol Carcinogen. 2019;58:196–205.

ACKNOWLEDGEMENTS
Not applicable.

AUTHOR CONTRIBUTIONS
JO, YZ, LY, PW, XF, XL, SZ and ZG collected the related paper and finished the manuscript and figures. CG and WX gave constructive guidance and made a critical revision. YH, YT, WZ, BX, MZ, JM, YL, GL and ZZ participated in the design of this review. All authors read and approved the final manuscript.

FUNDING INFORMATION
This study was supported by grants from the National Natural Science Foundation of China (82073135, 82072374, 82003243, 81972776, 81803025), the Overseas Expertise Introduction Project for Discipline Innovation (111 Project No. 111-2-12), the Natural Science Foundation of Hunan Province (2019JJ50354 and 2019JJ50780) and the Fundamental Research Funds for the Central South University (2021zzts0922).

COMPETING INTERESTS
The authors declare no competing interests.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE
Not applicable.

CONSENT TO PUBLISH
Not applicable.

ADDITIONAL INFORMATION
Correspondence and requests for materials should be addressed to Can Guo or Wei Xiong.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s), under exclusive licence to Springer Nature Limited 2021

British Journal of Cancer (2022) 126:1113 – 1124